Hardman Report1 Jul 2018 14:53
Thanks for posting.
Main bit fir me is onboard Trial Q4/18
Use of proceeds: The new capital will provide the working capital to progress its clinical programmes and for general corporate expenses. Of note, SCLP will start a late-stage melanoma combination study with SCIB1 + checkpoint inhibitor in 4Q’18, and a first-in-man breast clinical trial with Modi-1 in 1H’19.